2023 World Conference on Lung Cancer (Posters)-EP11.01. Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors

EP11.01. Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors - PDF(Abstract)

Back to course

Pdf Summary

In this study, the clinical significance of soluble PD-1 (sPD-1) and PD-L1 (sPD-L1) in the plasma of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI) was investigated. Blood samples were collected from 189 NSCLC patients before and after ICI treatment, and the levels of sPD-1 and sPD-L1 in the plasma were analyzed. The results showed that higher levels of sPD-L1 before treatment were associated with unfavorable progression-free survival (PFS) and overall survival (OS) in NSCLC patients treated with ICI monotherapy. However, this association was not observed in patients treated with ICI combined with chemotherapy. Additionally, higher levels of sPD-1 after treatment were associated with better OS in patients treated with anti-PD-1 monotherapy, while higher levels of sPD-L1 after treatment were associated with worse PFS and OS. Furthermore, the levels of sPD-L1 at baseline were correlated with other soluble factors released from the cell surface by zinc-binding proteases ADAM10/17. These findings indicate the clinical significance of pre-treatment sPD-L1, as well as post-treatment sPD-1 and sPD-L1, in NSCLC patients treated with ICI monotherapy. This study highlights the potential of sPD-1 and sPD-L1 as biomarkers for predicting the response to ICI treatment in NSCLC patients.

Asset Subtitle

Yoshiro Nakahara

Meta Tag

Speaker Yoshiro Nakahara

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

soluble PD-1

sPD-1

soluble PD-L1

sPD-L1

non-small cell lung cancer

NSCLC

immune checkpoint inhibitors

progression-free survival

overall survival

biomarkers